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Hydroxymethyl glutaryl coenzyme A inhibitors (‘statins’) are carcinogenic in rodents and an increased incidence of breast
cancer was reported among pravastatin users in one randomised trial. We conducted a case–control study in the General
Practice Research Database to evaluate the risk of breast cancer among 50- to 79-year old women treated with statins for
hyperlipidaemia. Case and control women were matched by age, general practice, duration of prescription history in the
General Practice Research Database, and index date. Adjusting for history of benign breast disease, body mass index, and use
of hormone replacement therapy, women currently treated with statins had an estimated relative risk for breast cancer of 1.0
(95% conﬁdence interval 0.6–1.6) compared to women without hyperlipidaemia. Untreated hyperlipidaemia was associated
with an increased risk of breast cancer (estimated relative risk 1.6; 95% conﬁdence interval 1.1–2.5). The estimated relative
risk among women currently receiving only non-statin lipid-lowering drugs was similar to that of women with untreated
hyperlipidaemia (1.8; 95% conﬁdence interval 0.9–3.4). We found no evidence for an increasing trend in breast cancer risk
with increasing duration of statin use (median duration 1.8 years, maximum 8.6 years).
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Hydroxymethyl glutaryl coenzyme A reductase inhibitors
(‘statins’) and ﬁbrates (the other leading class of cholesterol-
lowering drugs) can cause cancer in rodents (Newman and
Hulley, 1996). Clinical trials focused on cardiovascular mortality
and morbidity have had limited ability to assess the human carci-
nogenic potential of statins due to relatively short follow-up.
Among 13 trials reporting cancer incidence and deaths as
outcomes, with an average follow-up time of 3.3 years, no
evidence was found of an overall increased risk of cancer (relative
risk (RR) 1.03, 95% conﬁdence interval (CI) 0.90–1.17) or cancer
deaths (RR 0.95, 95% CI 0.74–1.21) among statin users (Hebert
et al, 1997). However, concern was raised by the only study that
reported on breast cancer risk, with 12 cases among pravastatin
users and only one case in a placebo group of similar size
(P=0.002) (Sacks et al, 1996).
We used the General Practice Research Database (GPRD), an
automated data source containing drug prescription and other
medical information on more than 3 million residents of the
UK, to study the possible relation of breast cancer to statin use
and hyperlipidaemia.
MATERIALS AND METHODS
We conducted a matched case–control study on the risk of breast
cancer in relation to use of statins, non-statin lipid-lowering
agents, and untreated hyperlipidaemia among women aged 50–
79 diagnosed with breast cancer in 1992–1998 in the UK General
Practice Research Database (GPRD).
General Practice Research Database (GPRD)
The GPRD started in 1988 and has been used extensively for
research studies; the subset of data we have used during the
past decade is of consistently high quality. (Jick et al, 1991)
Some 350 practices contributed to data used in this report.
In a previous study our group found that diagnoses of cancer
are validated in 95% of cases for whom further information
is obtained from general practitioners (Jick et al, 1997). Thirty
of 30 randomly selected probable cases of breast cancer were
conﬁrmed in an earlier review of their pathology report or
hospital discharge summary (Meier et al, 2000). Also, we
recently reported that the age-adjusted incidence rates of breast
cancer among women in the GPRD are closely similar to those
reported by the UK Ofﬁce of National Statistics (Kaye et al,
2000).
Base population
The base population consisted of subjects born from 1920 to 1955
for whom at least one lipid-lowering drug prescription (see Appen-
dix) was recorded in the GPRD (n=52924); subjects born in the
same years who had a recorded diagnosis of hyperlipidaemia
(ICD-8 codes 272.0, 272.1, and 272.3) but no recorded prescription
for any lipid-lowering drug (n=18189); and a random sample of
50000 women born in the same years who had no recorded diag-
nosis of hyperlipidaemia and no recorded prescription for any
lipid-lowering drug. We excluded women who underwent bone
marrow or other organ transplantation, received cyclosporine, or
had HIV infection or AIDS.
E
p
i
d
e
m
i
o
l
o
g
y
Received 21 May 2001; revised 20 July 2001; accepted 20 July 2001
*Correspondence: JA Kaye; Boston Collaborative Drug Surveillance
Program, Boston University School of Medicine, 11 Muzzey Street, Lexing-
ton, MA 02421, USA; E-mail: jkaye@bu.edu
British Journal of Cancer (2002) 86, 1436–1439
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comCases and controls
From the base population we identiﬁed all women with newly
diagnosed breast cancer at age 50–79. Because in situ and invasive
cancers are not coded separately in the database, both were
included in this study. On the basis of individual review of compu-
ter proﬁles in which prescription information was suppressed, we
excluded cases with a prior history of breast or other cancer, those
in whom the diagnosis of breast cancer appeared uncertain, and
those ﬁrst diagnosed with breast cancer at the time of death. We
also excluded cases with less than 5 years of recorded prescription
information in the GPRD.
From the base population we matched up to ﬁve controls to
each case by sex, year of birth (within 2 years), date of ﬁrst
recorded prescription in the GPRD (within 1 year), and general
practice. Controls were required to have evidence of active
follow-up in the database on the date their matched case was diag-
nosed (‘index date’). The same exclusions were applied to the
controls as to the cases.
Exposure assessment
The use of a lipid-lowering agent was ‘current’ if a subject had at
least one prescription within 6 months before the index date. Past
use was deﬁned as having at least one recorded prescription more
than 6 months before the index date. Subjects who were current or
past users of both statins and non-statins were classed as current or
past statin users only. Untreated hyperlipidaemia was deﬁned as a
recorded diagnosis of hyperlipidaemia (see ‘Base population’ for
diagnostic codes) at any time before the index date in the absence
of treatment.
To assess the effect of duration of treatment for current users,
we calculated the time interval from each subject’s ﬁrst prescription
for a given class of drug to her last prescription plus the number of
days covered by the last prescription up to the index date.
Other covariates
We evaluated body mass index (BMI), current or past hormone
replacement therapy (HRT), and history of benign breast disease
as potential confounding factors. BMI was calculated from the ﬁrst
recorded height and weight measurement in each subject’s compu-
ter record, and the measurement of weight must have preceded the
index date. We considered a woman to have a history of benign
breast disease if she had a diagnosis of ﬁbrocystic disease, intraduc-
tal papilloma, or ﬁbroadenoma recorded at any time before her
index date. We deﬁned HRT as any recorded prescriptions for
systemic oestrogen (including patches but excluding creams) either
alone or in combination with a progestin. We distinguished
current and past users according to whether they received any
HRT prescriptions within 6 months before their index date.
Subjects were designated by coded GPRD record numbers and
we had no access to personal identifying information. The study
protocol was approved by the Scientiﬁc and Ethical Advisory
Group of the GPRD.
Statistical methods
We used conditional logistic regression to estimate odds ratios and
95% conﬁdence intervals. The reference group for model-adjusted
analyses comprised women who had no diagnosis of hyperlipidae-
mia, had no recorded prescriptions for a lipid-lowering agent
before their index date, did not use hormone replacement therapy,
had low body mass index (524 kg m
2) and had no history of
benign breast disease. We report estimated odds ratios as ‘relative
risks’ with 95% conﬁdence limits. Statistical calculations were
performed using SAS, version 8.01 (SAS Institute, Inc., Cary, NC,
USA).
RESULTS
We identiﬁed 224 women aged 50 to 79 with incident breast cancer
in the base population and 1009 controls matched by age, sex,
general practice, duration of prescription drug history in the
GPRD, and index date.
Characteristics of the cases and controls are listed in Table 1.
Body mass index (BMI) was greater than 28 kg m
2 in a higher
proportion of cases than controls. Although hormone replacement
therapy (HRT) was used by approximately the same proportion of
cases as controls, current HRT use was more frequent among cases.
Cases were more likely than controls to have a history of benign
breast disease.
Table 2 lists the proportions of cases and controls with a
recorded history of hyperlipidaemia and treatment with lipid-
lowering drugs. Untreated hyperlipidaemia was more frequent
among cases than controls.
Multivariable model-adjusted relative risks for breast cancer
according to exposure group are presented in Table 3.
Compared with women without hyperlipidaemia, the relative
risk (RR) for breast cancer among women currently treated
with statins was 1.0 (0.6–1.6). Among the 200 current statin
users, 26 were current users of pravastatin (two cases and 24
controls), the RR among women currently treated with pravas-
tatin compared to women without hyperlipidaemia was 0.4
(0.1–1.8).
Compared to women without hyperlipidaemia, the risk was
modestly increased among women with untreated hyperlipidae-
mia (RR 1.6 (1.1–2.5)) and among those with
hyperlipidaemia currently treated with non-statin lipid-lowering
drugs (RR 1.8 (0.9–3.4)). Compared with the same reference
group, the RR for breast cancer among women with past statin
use was similar to that of current statin users, and past non-
statin users had a risk that was nearly the same as that of
current non-statin users.
Among current statin users, the median duration of treat-
ment was 1.8 years and the maximum duration was 8.6
years. The data show no trend in risk with increasing duration
of current statin use: the adjusted RRs of breast cancer were 1.1
(0.4–2.8) among six cases and 28 controls with current statin
use of duration 3 to 5 years and 1.1 (0.4–3.0) among ﬁve
cases and 26 controls with current statin use of duration longer
than 5 years.
Current long-term use of hormone replacement therapy (HRT)
was independently associated with a cumulative increase in risk (up
to RR 2.1 (1.2–3.7) for women with 24 or more prescriptions
compared with non-users; see Table 3), while past users had a
somewhat decreased risk (RR 0.6 (0.4–1.0)). A history of benign
breast disease was associated with an increased risk of breast cancer
(RR 1.6 (0.8–3.1)). Women with BMI greater than 28 kg m
2 had a
slightly increased RR of 1.4 (0.9–2.1) compared to women with
BMI less than 24 kg m
2.
We considered that an association with hyperlipidaemia
might occur spuriously if hyperlipidaemia were diagnosed inci-
dentally during the evaluation of patients with suspicious breast
lesions. Therefore, we restricted a secondary analysis to case–
control sets in which the ﬁrst diagnosis of hyperlipidaemia
(if any) or prescription for a lipid-lowering drug (if any)
was recorded 6 months or more before the index date. In this
analysis of 1095 subjects (208 cases and 887 controls), the RRs
among women with untreated hyperlipidaemia (1.9 (1.1–2.6))
and women who had hyperlipidaemia treated with non-statin
drugs either currently (1.8 (0.9–3.9)) or in the past (2.0
(0.9–4.4)) were similar to those in the primary analysis. This
additional analysis provided further evidence that there was no
increased risk among women treated with statins either
currently (RR 0.8 (0.5–1.4)) or in the past (RR 1.2 (0.6–
2.6)).
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In this population-based, matched case–control study, neither
current nor past use of HMG-CoA reductase inhibitors (‘statins’)
showed any association with the risk of breast cancer. Longer dura-
tion of statin use was not associated with any increased risk of
breast cancer.
Women with hyperlipidaemia who did not use lipid-lowering
drugs or who used exclusively non-statin lipid-lowering drugs
had a modestly increased risk compared to women without
hyperlipidaemia. This is an unexpected ﬁnding. The few epide-
miologic studies that have directly evaluated the relation of
hyperlipidaemia to breast cancer risk have found little evidence
for any association. In a follow-up study of over 95000 women
in the western US, no increased risk of breast cancer appeared
following a single elevated serum cholesterol measurement at the
time of enrolment (Hiatt et al, 1982) In a case–control study
nested in the same cohort, there was no overall association
between high-density lipoprotein cholesterol (HDL-C) and breast
cancer, although modest indirect and direct associations were
found for HDL-C among premenopausal and post-menopausal
women, respectively (Moorman et al, 1998). The Framingham
study found no association between cholesterol levels and the
incidence of any cancer among women (Williams et al, 1981).
However, cholesterol and triglyceride levels were increased
among Greek women with breast cancer relative to controls
(Alexopoulos et al, 1987).
The observed increase in risk of breast cancer related to hyper-
lipidaemia in our study was modest and could have arisen through
unrecognized selection or information bias, unmeasured confound-
ing, or by chance. It would therefore be inappropriate to conclude
that statin treatment lowered the risk of breast cancer in our study,
simply because women treated for hyperlipidaemia were at no
greater risk than normolipemic women. There was no effect of
the duration of current statin use on the risk of breast cancer,
and the 95% conﬁdence intervals for relative risk of breast cancer
among women with untreated hyperlipidaemia and current statin
users overlap considerably.
As reported in several other studies (Collaborative Group on
Hormonal Factors in Breast Cancer, 1997; Colditz and Rosner,
2000; Schairer et al, 2000), current use of hormone replacement
therapy (HRT) was associated with an increased risk of breast
cancer, and the risk increased with the number of HRT
prescriptions. We were not able to analyse reproductive risk
factors because these data are not coded routinely in the GPRD.
However, it is improbable that such factors would confound
our results substantially because they are unlikely to determine
anti-hypercholesterolemia treatment.
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Table 1 Characteristics of cases and controls
Cases Controls Total
N (%) N (%) N (%)
Age
50–59 81 (36) 374 (37) 455 (37)
60–69 94 (42) 436 (43) 530 (43)
70–79 49 (22) 199 (20) 248 (20)
Body mass index
524 kg m
2 55 (24) 270 (27) 325 (26)
24–28 kg m
2 66 (29) 322 (32) 388 (31)
428 kg m
2 69 (31) 261 (26) 330 (27)
Unknown 34 (15) 156 (15) 190 (15)
Use of hormone
replacement therapy
Current 60 (27) 185 (18) 245 (20)
Past 18 (8) 138 (14) 156 (13)
None 146 (65) 686 (68) 832 (67)
History of benign
breast disease
Yes 15 (7) 39 (4) 54 (4)
No 209 (93) 970 (96) 1179 (96)
Total 224 1009 1233
Table 2 Exposure classiﬁcation of cases and controls
Cases Controls Total
N (%) N (%) N (%)
No hyperlipidaemia or use
of lipid-lowering agents
102 (46) 517 (51) 619 (50)
Hyperlipidaemia alone 56 (25) 208 (21) 264 (21)
Use of lipid-lowering drugs
Current use
Statins 31 (14) 169 (17) 200 (16)
Non-statins 15 (7) 48 (5) 63 (5)
Past use
Statins 10 (4) 40 (4) 50 (4)
Non-statins 10 (4) 27 (3) 37 (3)
Total 224 1009 1233
Table 3 Multivariable model-adjusted relative risks of breast cancer with
use of lipid-lowering drugs, untreated hyperlipidaemia, and other covariates
Variable Relative risk (95% CI)
No hyperlipidaemia or use of lipid-lowering drugs 1.0 reference
Untreated hyperlipidaemia 1.6 (1.1–2.5)
Use of lipid-lowering drugs
Current use
Statins 1.0 (0.6–1.6)
Non-statins 1.8 (0.9–3.4)
Past use
Statins 1.3 (0.6–2.8)
Non-statins 2.0 (0.9–4.3)
Hormone replacement therapy
None 1.0 reference
Current use
1–5 prescriptions 1.0 (0.4–2.5)
6–11 prescriptions 1.3 (0.5–3.0)
12–23 prescriptions 1.4 (0.8–2.5)
24+ prescriptions 2.1 (1.2–3.7)
Past use 0.6 (0.4–1.0)
Body mass index
524 kg m
2 1.0 reference
24–28 kg m
2 1.0 (0.7–1.5)
428 kg m
2 1.4 (0.9–2.1)
Unknown 1.0 (0.6–1.7)
History of benign breast disease
None 1.0 reference
Any 1.6 (0.8–3.1)
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